

United States Patent and Trademark Office

Jis.

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/673,785	12/29/2000	John Nelson	41934/23838	4216	
23973 75	590 01/14/2005		EXAM	EXAMINER	
DRINKER BIDDLE & REATH			KAM, CH	KAM, CHIH MIN	
ONE LOGAN	SQUARE				
18TH AND CHERRY STREETS			ART UNIT	PAPER NUMBER	
PHILADELPH	IA, PA 19103-6996		1653		

DATE MAILED: 01/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

·		Application No.	Applicant(s)				
Office Action Summary		09/673,785	NELSON ET AL.				
		Examiner	Art Unit				
		Chih-Min Kam	1653				
Period fo	The MAILING DATE of this communication a or Reply	appears on the cover sheet	with the correspondence ac	ddress			
THE - Exte after - If the - If NO - Failt Any	ORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION msions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a compensation of the provision of the period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by stareply received by the Office later than three months after the may be patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may reply within the statutory minimum of od will apply and will expire SIX (6) Note, cause the application to become	y a reply be timely filed thirty (30) days will be considered time MONTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on 22	October 2004.					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ T	his action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims		·				
4)⊠ 5)⊠ 6)⊠	Claim(s) 1-10,12-20 and 22-27 is/are pendir 4a) Of the above claim(s) is/are withd Claim(s) 1 and 3-8 is/are allowed. Claim(s) 2,9,10,12-20 and 22-27 is/are reject Claim(s) is/are objected to. Claim(s) are subject to restriction and	rawn from consideration.					
Applicat	ion Papers						
9)[The specification is objected to by the Exami	iner.					
10)[D) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
, 11) <u></u>	Replacement drawing sheet(s) including the corr The oath or declaration is objected to by the			• •			
Priority ι	under 35 U.S.C. § 119						
a)l	Acknowledgment is made of a claim for forei All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure See the attached detailed Office action for a li	ents have been received. ents have been received in riority documents have be eau (PCT Rule 17.2(a)).	n Application No en received in this National	Stage			
	,	•					
Attachmen	t(s)						
	e of References Cited (PTO-892)		w Summary (PTO-413)				
3) 🔲 Infor	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date		lo(s)/Mail Date of Informal Patent Application (PTC 	D-152)			

DETAILED ACTION

Status of the Claims

1. Claims 1-10, 12-20 and 22-27 are pending.

Applicants' amendment filed October 22, 2004 is acknowledged, and applicants' response has been fully considered. Claim 1-6, 9, 10, 12-17, 19, 20 and 22-25 have been amended, and claim 21 has been cancelled. Therefore, claims 1-10, 12-20 and 22-27 are examined.

Rejection Withdrawn

Claim Rejections - 35 USC § 101

2. The previous rejection of claims 1-4, 9, 10 and 19-23 under 35 U.S.C.101, is withdrawn in view of applicants' amendment to the claim, applicants' cancellation of the claim, and applicants' response at pages 9-10 in the amendment filed October 22, 2004.

Claim Rejections - 35 USC § 112

- 3. The previous rejection of claims 1-10 and 12-27, under 35 U.S.C.112, first paragraph, is withdrawn in view of applicants' amendment to the claim, applicants' cancellation of the claim, and applicants' response at pages 12-14 in the amendment filed October 22, 2004.
- 4. The previous rejection of claims 1-10 and 12-27, under 35 U.S.C.112, second paragraph, is withdrawn in view of applicants' amendment to the claim, applicants' cancellation of the claim, and applicants' response at page 14 in the amendment filed October 22, 2004.

Application/Control Number: 09/673,785 Page 3

Art Unit: 1653

Claim Objections

5. Claims 19, 20 and 22-27 are objected to because of the use of the term " $\alpha\alpha$ -dialkyl substituted amino acid", which should be " α , α -dialkyl substituted amino acid". Appropriate corrections are required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 6. Claims 2, 9, 10, 12-20 and 22-27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 7. Claims 2, 9, 10, 12-20 and 22-27 are indefinite because the claims recite "the synthetic peptide factor having an N-terminal amino acid residue and a C-terminal amino acid residue", and it also indicates the N-terminal amino acid residue, the C-terminal amino acid residue, and the cysteine residue of murine epidermal growth factor, it is not clear which peptide (the synthetic peptide factor or murine epidermal growth factor) the N-terminal amino acid residue, the C-terminal amino acid residue, and the cysteine residue refer to since the peptide factor, which comprises amino acid residues 33 to 42 of murine epidermal growth factor, is different from the murine epidermal growth factor. Claims 9, 10, 13, 14, 16-18, 22, 23, 26 and 27 are included in this rejection for being dependent on a rejected claim and not correcting the deficiency of the claim from which they depend.

Conclusions

Application/Control Number: 09/673,785 Page 4

Art Unit: 1653

8. Claims 2, 9, 10, 12-20 and 22-27 are rejected, and it appears that claims 1 and 3-8 are free of art and allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Oblik

Chih-Min Kam, Ph. D.

Patent Examiner

CMK

January 11, 2005